DHP-Evertry Partners to Expand Digital Healthcare Base

Digital healthcare startup-focused investment firm Digital Healthcare Partners (DHP) and digital healthcare specialized clinical research organization (CRO) Evertree recently announced on the 13th that they have signed a memorandum of understanding (MOU) to promote digital healthcare licensing and commercialization.

Choi Yoon-seop, CEO of Digital Healthcare Partners (DHP) (left), and Shin Jae-yong, CEO of Evertry, are posing for a commemorative photo at the MOU signing ceremony.
[Photo by DHP]

Through this MOU, the two companies plan to engage in broad cooperation, including discovering promising startups in the digital healthcare sector, investment screening, as well as regulatory-related tasks such as clinical research and licensing.

Since its establishment in 2016, DHP has invested in and nurtured more than 40 domestic and international digital healthcare startups. Since its founding in 2022, Evertree has conducted licensing for over 20 software medical devices (SaMD) and provided commercialization consulting related to insurance for more than five cases. It has offered end-to-end consulting and clinical contract services for domestic and international digital healthcare startups, covering product development, clinical trials, licensing, and commercialization. In particular, it is recognized for its rich experience and expertise in clinical trials and licensing related to SaMD such as medical artificial intelligence (AI) and digital therapeutics (DTx). The two companies aim to leverage their synergy through this MOU, specializing in investment and clinical contract services in the digital healthcare field, to further expand the foundation of the digital healthcare industry.

Choi Yoonseop, CEO of DHP, said, “For digital healthcare startups to enter the market, they must go through the challenging processes of clinical research, licensing, and insurance reimbursement.” He added, “Through collaboration with Evertree, which has abundant experience and expertise in digital healthcare clinical trials, regulation, and reimbursement, we will more faithfully support the growth of startups invested by DHP.”

Shin Jaeyong, CEO of Evertree, also stated, “DHP is the accelerator that understands the digital healthcare sector best in Korea.” He added, “Evertree will support DHP’s portfolio companies to use resources efficiently and grow rapidly by preventing the need to repeat clinical trials two or three times from the early product development stage.”